RGC vs AMLX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RGC · Regencell Bioscience$5.27 ▲ 0.00%
AMLX · Amylyx Pharmaceuticals$29.50 ▲ 6.81%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RGC -61.9%
- AMLX +142.2%
Head to head
| Metric | RGC | AMLX |
|---|---|---|
| Price | $5.27 | $29.50 |
| Change today | ▲ 0.00% | ▲ 6.81% |
| Market cap | $2.61B | $3.79B |
| Return, 3 months | -0.2% | +30.1% |
| Return, year to date | -74.9% | +144.2% |
| Return, 1 year | -59.5% | +139.6% |
| P/E (TTM) | – | – |
| P/B | 195.2 | 5.0 |
| P/E percentile vs own 5y | 35th | 3rd |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +6.0% | – |
| Net profit growth (YoY) | -46.4% | -4.8% |
| Gross margin | 62.4% | – |
| Operating margin | 10.5% | – |
| Net margin | 3.4% | – |
| Return on equity | -128.5% | -74.7% |
| Analyst target vs. price | – | +56.4% |
| Analyst buy share | – | 100% |
| RSI (14) | 34 | 54 |
| 30-day volatility | 128.0% | 49.1% |
| Max drawdown, 1 year | -91.0% | -33.6% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- AMLX is the largest of the group by market value.
- AMLX has returned the most over the past year.
- AMLX has been the calmest stock over the last 30 days.